am 251 and clindamycin
am 251 has been researched along with clindamycin in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Augusto, PSA; Braga, AV; Coelho, MM; Costa, FC; Costa, SOAM; Dutra, MMGB; Goulart, FA; Machado, RR; Melo, ISF; Morais, MI; Rodrigues, FF | 1 |
Other Studies
1 other study(ies) available for am 251 and clindamycin
| Article | Year |
|---|---|
Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; Chemokine CXCL1; Clindamycin; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Inflammation; Male; Mice; Pain; Piperidines; Pyrazoles; Tumor Necrosis Factor-alpha | 2020 |